Phase II Study of Radiotherapy Followed by Durvalumab and Ceralasertib in Stage III NSCLC Patients With Thoracic Relapses +/- Oligometastases After PACIFIC Regimen

NCT06680050 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

21

Enrollment

OTHER

Sponsor class

Conditions

Non Small Cell Lung Cancer NSCLC

Interventions

DRUG: Durvalumab (MEDI4736)
DRUG: Ceralasertib
RADIATION: radiotherapy

Sponsor

Mario Negri Institute for Pharmacological Research